MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c)

MOTS-c (Mitochondrial-derived peptide from Open Reading Frame of the 12S rRNA, type c) was described in 2015 as one of several 'mitochondrial-derived peptides' — short peptides encoded within the mitochondrial genome rather than nuclear DNA. It's a 16-amino acid peptide whose circulating levels decline with age.^[1]

MOTS-c was first described in 2015 by Changhan David Lee and Pinchas Cohen at USC, identified through a systematic search for peptides encoded within mitochondrial DNA — a genome long assumed to encode only the small set of canonical respiratory-chain proteins. The discovery established a new biology: mitochondrial-derived peptides ("mitokines") that act outside their organelle of origin to regulate cellular metabolism. Circulating MOTS-c levels were shown to decline with age, framing the peptide within the broader literature on mitochondrial dysfunction in aging.

Since 2015, MOTS-c has been the subject of growing preclinical and translational research, including investigation in metabolic disease, exercise physiology, and age-related muscle dysfunction. Early-phase human studies are underway, and analog development is an active commercial area.

MOTS-c acts in multiple cellular contexts:

• Activates AMPK, the master energy-sensing pathway (overlapping with metformin, exercise, and caloric restriction)
• Translocates to the nucleus under stress and modulates gene expression (folate-methionine metabolism, stress response)
• Improves glucose uptake and insulin sensitivity in skeletal muscle
• Promotes browning of white adipose tissue in rodents

Pharmacokinetic data for MOTS-c is largely preclinical. Plasma levels are not sustained for long periods after administration, but functional effects on AMPK signaling and metabolic gene expression have been observed downstream of even short exposures, suggesting the relevant pharmacodynamic action occurs through transient signaling rather than sustained occupancy of a defined receptor.

The peer-reviewed literature on MOTS-c is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).

This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.

In animal research, subcutaneous and intraperitoneal administration have been used. Grey-market human use is typically subcutaneous. No clinical protocol exists.

MOTS-c represents some of the more interesting longevity-related peptide biology. The rodent data is genuinely striking — the kind of results that would justify serious human trials. But until those trials are run, injectable MOTS-c in healthy humans is an inference, not an evidence-based intervention. Worth tracking as the field develops.